Retrospective analysis correlates HPV-DNA and p16 IHC with survival in OPSCC, suggesting combined testing may improve outcomes.
Key Points
Survival rates improved with both hpv-dna testing and p16 immunohistochemistry in oropharyngeal cancer patients.
Among 71 patients assessed, 51 tested positive for p16 and 49 for hpv-dna, indicating a relationship with extended survival.
Retrospective analysis over 24 years highlighted significant discrepancies in 18 patients between p16 and hpv-dna test results regarding survival predictions.
Both tests offer advantages and disadvantages, and reliance solely on p16 may limit accurate prognosis for oropharyngeal cancer.